Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
- PMID: 34872510
- PMCID: PMC8646009
- DOI: 10.1186/s12879-021-06921-y
Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
Abstract
Background: Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation.
Methods: This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection.
Results: The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays.
Conclusions: High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
Keywords: Antibody detection; Chemiluminescence assay; ELISA; Microneutralization assay; SARS-coronavirus-2.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.PLoS One. 2022 Apr 27;17(4):e0263316. doi: 10.1371/journal.pone.0263316. eCollection 2022. PLoS One. 2022. PMID: 35476709 Free PMC article.
-
Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.Microbiol Spectr. 2021 Oct 31;9(2):e0073321. doi: 10.1128/Spectrum.00733-21. Epub 2021 Sep 29. Microbiol Spectr. 2021. PMID: 34585943 Free PMC article.
-
Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance.Open Forum Infect Dis. 2021 May 10;8(7):ofab239. doi: 10.1093/ofid/ofab239. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34258311 Free PMC article.
-
Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.J Clin Virol. 2020 Aug;129:104539. doi: 10.1016/j.jcv.2020.104539. Epub 2020 Jul 6. J Clin Virol. 2020. PMID: 32679298 Free PMC article.
-
Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays.Intervirology. 2022;65(4):224-229. doi: 10.1159/000522479. Epub 2022 Feb 8. Intervirology. 2022. PMID: 35134813 Free PMC article.
Cited by
-
Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.PLoS One. 2022 Apr 27;17(4):e0263316. doi: 10.1371/journal.pone.0263316. eCollection 2022. PLoS One. 2022. PMID: 35476709 Free PMC article.
-
Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients.PLoS One. 2024 Apr 16;19(4):e0298033. doi: 10.1371/journal.pone.0298033. eCollection 2024. PLoS One. 2024. PMID: 38626137 Free PMC article.
References
-
- Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi: 10.1126/sciimmunol.abc8413. - DOI - PMC - PubMed
-
- Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing in clinical and public health settings. 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-g.... Updated 17 Mar 2021. Accessed 15 June 2021.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous